Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity
Open Access
- 7 June 2022
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 39 (10) , 110930
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01s AI107731, AI125198)
- National Institute of Health
This publication has 40 references indexed in Scilit:
- High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus InfectionJournal of Virology, 2013
- The global distribution and burden of dengueNature, 2013
- Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 yearsHuman Vaccines & Immunotherapeutics, 2012
- Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, PeruVaccine, 2012
- Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric Yellow Fever 17D/Dengue virusesVirology, 2012
- Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico CityThe Pediatric Infectious Disease Journal, 2011
- Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 VirusesPLOS Pathogens, 2010
- A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive AdultsThe Journal of Infectious Diseases, 2010
- Molecular evolution of dengue viruses: Contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral diseaseInfection, Genetics and Evolution, 2009
- Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman PrimatesJournal of Virology, 2004